The post RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next? appeared on BitcoinEthereumNews.com. Secretary of Health and Human Services Robert F. Kennedy Jr. The Associated Press Tylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop there. Tylenol may be only the beginning. For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and Human Services, he’s begun turning his opinions into public policy. His Make American Healthy Again initiative has already made it harder for people to get vaccinated against COVID-19 and pushed unverified claims about Tylenol, and he’s just getting started. So what might be next? Kennedy’s already told us. On Monday, Kennedy and FDA Commissioner Marty Makary wrote in a letter to 22 Republican attorneys general that the FDA was reviewing evidence about the safety of abortion drug, mifepristone, which is used in nearly two-thirds of medical abortions. If access to the pill were restricted, it would significantly cut back on abortion access. Another big target: antidepressants. During Kennedy’s confirmation hearings, he falsely claimed that people have a harder time stopping the use of serotonin-based antidepressants “than people have getting off of heroin.” He’s also made the unfounded claim that teenagers who use them are more likely to commit school shootings (they aren’t.) One of the goals of Kennedy’s “Make America Healthy Again” movement is to “assess the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors.” Any restrictions on them would be a grave concern to the approximately 11% of the population that uses them to treat depression, anxiety and other issues. Another frequent target of Kennedy’s are statins, which more than 92 million Americans… The post RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next? appeared on BitcoinEthereumNews.com. Secretary of Health and Human Services Robert F. Kennedy Jr. The Associated Press Tylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop there. Tylenol may be only the beginning. For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and Human Services, he’s begun turning his opinions into public policy. His Make American Healthy Again initiative has already made it harder for people to get vaccinated against COVID-19 and pushed unverified claims about Tylenol, and he’s just getting started. So what might be next? Kennedy’s already told us. On Monday, Kennedy and FDA Commissioner Marty Makary wrote in a letter to 22 Republican attorneys general that the FDA was reviewing evidence about the safety of abortion drug, mifepristone, which is used in nearly two-thirds of medical abortions. If access to the pill were restricted, it would significantly cut back on abortion access. Another big target: antidepressants. During Kennedy’s confirmation hearings, he falsely claimed that people have a harder time stopping the use of serotonin-based antidepressants “than people have getting off of heroin.” He’s also made the unfounded claim that teenagers who use them are more likely to commit school shootings (they aren’t.) One of the goals of Kennedy’s “Make America Healthy Again” movement is to “assess the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors.” Any restrictions on them would be a grave concern to the approximately 11% of the population that uses them to treat depression, anxiety and other issues. Another frequent target of Kennedy’s are statins, which more than 92 million Americans…

RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next?

Secretary of Health and Human Services Robert F. Kennedy Jr.

The Associated Press

Tylenol may be only the beginning.

For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and Human Services, he’s begun turning his opinions into public policy. His Make American Healthy Again initiative has already made it harder for people to get vaccinated against COVID-19 and pushed unverified claims about Tylenol, and he’s just getting started. So what might be next? Kennedy’s already told us.

On Monday, Kennedy and FDA Commissioner Marty Makary wrote in a letter to 22 Republican attorneys general that the FDA was reviewing evidence about the safety of abortion drug, mifepristone, which is used in nearly two-thirds of medical abortions. If access to the pill were restricted, it would significantly cut back on abortion access.

Another big target: antidepressants. During Kennedy’s confirmation hearings, he falsely claimed that people have a harder time stopping the use of serotonin-based antidepressants “than people have getting off of heroin.” He’s also made the unfounded claim that teenagers who use them are more likely to commit school shootings (they aren’t.)

One of the goals of Kennedy’s “Make America Healthy Again” movement is to “assess the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors.” Any restrictions on them would be a grave concern to the approximately 11% of the population that uses them to treat depression, anxiety and other issues.

Another frequent target of Kennedy’s are statins, which more than 92 million Americans take to prevent heart disease and lower cholesterol. Most studies find that statins are both safe and help to prevent serious heart disease, which is the number one killer of Americans.

Yet Children’s Health Defense, the organization Kennedy founded, has published articles questioning the relationship of cholesterol to heart disease, with one calling them “overprescribed and unnecessary.” And earlier this year, as HHS Secretary, Kennedy claimed on a podcast that pharmaceutical companies manipulated studies to show they work.

One of the rationales for the agency’s recent crackdown on pharmaceutical ads is increased uptake of the drugs. Statins were the drugs of an older generation. Also in the crosshairs are newer innovations, like the increasingly popular GLP-1s used to treat diabetes (Ozempic, Mounjaro) and obesity (Wegovy, Zepbound). These drugs have recently been approved for additional health problems, such as sleep apnea, and are even being investigated for drug addiction.

That remarkable success hasn’t stopped Kennedy from criticizing their cost (they are expensive) and making false claims about them. For example, he falsely said that Novo Nordisk, which makes Ozempic, doesn’t market it in Europe. (It does.) He’s also said that ensuring Americans eat a good diet would solve the obesity problem–but multiple clinical studies have shown that GLP-1s are vastly superior to diet alone to helping people not only lose weight but keep it off.

In a first jab at their use, Kennedy rejected a plan to have Medicare cover the cost of GLP-1 drugs for obesity, which would have given 7 million Americans access to them, in April. (Medicare already covers these treatments for diabetes.) Could more restrictions on their use be seen down the road?

“They’re counting on selling it to Americans because we’re so stupid and so addicted to drugs,” Kennedy told viewers of Fox News about Ozempic and its manufacturer Novo Nordisk.

It’s not clear what, if anything, would change his mind.

MORE FROM FORBES

ForbesTrump’s Unproven Claims About Tylenol And Autism Are Reaching Millions On TikTokForbesRFK Jr.’s CDC Is Poised To Restrict Vaccines Even FurtherForbesThis Startup Hit A $3.25 Billion Valuation Building Software To Fix Drug Pricing

Source: https://www.forbes.com/sites/alexknapp/2025/09/26/rfk-jr-is-targeting-vaccines-and-tylenol-are-prozac-and-ozempic-next/

Market Opportunity
null Logo
null Price(null)
--
----
USD
null (null) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Why This New Trending Meme Coin Is Being Dubbed The New PEPE After Record Presale

Why This New Trending Meme Coin Is Being Dubbed The New PEPE After Record Presale

The post Why This New Trending Meme Coin Is Being Dubbed The New PEPE After Record Presale appeared on BitcoinEthereumNews.com. Crypto News 17 September 2025 | 20:13 The meme coin market is heating up once again as traders look for the next breakout token. While Shiba Inu (SHIB) continues to build its ecosystem and PEPE holds onto its viral roots, a new contender, Layer Brett (LBRETT), is gaining attention after raising more than $3.7 million in its presale. With a live staking system, fast-growing community, and real tech backing, some analysts are already calling it “the next PEPE.” Here’s the latest on the Shiba Inu price forecast, what’s going on with PEPE, and why Layer Brett is drawing in new investors fast. Shiba Inu price forecast: Ecosystem builds, but retail looks elsewhere Shiba Inu (SHIB) continues to develop its broader ecosystem with Shibarium, the project’s Layer 2 network built to improve speed and lower gas fees. While the community remains strong, the price hasn’t followed suit lately. SHIB is currently trading around $0.00001298, and while that’s a decent jump from its earlier lows, it still falls short of triggering any major excitement across the market. The project includes additional tokens like BONE and LEASH, and also has ongoing initiatives in DeFi and NFTs. However, even with all this development, many investors feel the hype that once surrounded SHIB has shifted elsewhere, particularly toward newer, more dynamic meme coins offering better entry points and incentives. PEPE: Can it rebound or is the momentum gone? PEPE saw a parabolic rise during the last meme coin surge, catching fire on social media and delivering massive short-term gains for early adopters. However, like most meme tokens driven largely by hype, it has since cooled off. PEPE is currently trading around $0.00001076, down significantly from its peak. While the token still enjoys a loyal community, analysts believe its best days may be behind it unless…
Share
BitcoinEthereumNews2025/09/18 02:50
Real estate, crypto, bonds, AI stocks and gold defined global market trades in 2025

Real estate, crypto, bonds, AI stocks and gold defined global market trades in 2025

The post Real estate, crypto, bonds, AI stocks and gold defined global market trades in 2025 appeared on BitcoinEthereumNews.com. 2025 was packed with high-stakes
Share
BitcoinEthereumNews2025/12/29 06:12
Headwind Helps Best Wallet Token

Headwind Helps Best Wallet Token

The post Headwind Helps Best Wallet Token appeared on BitcoinEthereumNews.com. Google has announced the launch of a new open-source protocol called Agent Payments Protocol (AP2) in partnership with Coinbase, the Ethereum Foundation, and 60 other organizations. This allows AI agents to make payments on behalf of users using various methods such as real-time bank transfers, credit and debit cards, and, most importantly, stablecoins. Let’s explore in detail what this could mean for the broader cryptocurrency markets, and also highlight a presale crypto (Best Wallet Token) that could explode as a result of this development. Google’s Push for Stablecoins Agent Payments Protocol (AP2) uses digital contracts known as ‘Intent Mandates’ and ‘Verifiable Credentials’ to ensure that AI agents undertake only those payments authorized by the user. Mandates, by the way, are cryptographically signed, tamper-proof digital contracts that act as verifiable proof of a user’s instruction. For example, let’s say you instruct an AI agent to never spend more than $200 in a single transaction. This instruction is written into an Intent Mandate, which serves as a digital contract. Now, whenever the AI agent tries to make a payment, it must present this mandate as proof of authorization, which will then be verified via the AP2 protocol. Alongside this, Google has also launched the A2A x402 extension to accelerate support for the Web3 ecosystem. This production-ready solution enables agent-based crypto payments and will help reshape the growth of cryptocurrency integration within the AP2 protocol. Google’s inclusion of stablecoins in AP2 is a massive vote of confidence in dollar-pegged cryptocurrencies and a huge step toward making them a mainstream payment option. This widens stablecoin usage beyond trading and speculation, positioning them at the center of the consumption economy. The recent enactment of the GENIUS Act in the U.S. gives stablecoins more structure and legal support. Imagine paying for things like data crawls, per-task…
Share
BitcoinEthereumNews2025/09/18 01:27